DrugPatentWatch Database Preview
Ivosidenib - Generic Drug Details
What are the generic sources for ivosidenib and what is the scope of patent protection?
Ivosidenib
is the generic ingredient in one branded drug marketed by Agios Pharms Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ivosidenib has sixty patent family members in thirty-one countries.
One supplier is listed for this compound.
Summary for ivosidenib
| International Patents: | 60 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 28 |
| Clinical Trials: | 9 |
| Patent Applications: | 25 |
| DailyMed Link: | ivosidenib at DailyMed |
Recent Clinical Trials for ivosidenib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Jason Luke | Phase 2 |
| Agios Pharmaceuticals, Inc. | Phase 2 |
| National Cancer Institute (NCI) | Phase 1 |
Synonyms for ivosidenib
| (2S)-1-(4-Cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-glycinamide |
| (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N- |
| (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| 1448347-49-6 |
| A14386 |
| AG-120 |
| ag-120-Ivosidenib |
| AG120 |
| AS-35058 |
| CHEMBL3989958 |
| CS-5122 |
| D11090 |
| EX-A992 |
| Glycinamide, 1-(4-cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-, (2S)- |
| GTPL9217 |
| HY-18767 |
| Ivosidenib (AG-120) |
| Ivosidenib (USAN/INN) |
| Ivosidenib [INN] |
| Ivosidenib [USAN] |
| Ivosidenib [WHO-DD] |
| MFCD29036964 |
| NCGC00476170-04 |
| NCGC00476170-06 |
| Q2PCN8MAM6 |
| RG120 |
| s8206 |
| SCHEMBL15122512 |
| Tibsovo |
| UNII-Q2PCN8MAM6 |
| ZINC205136523 |
US Patents and Regulatory Information for ivosidenib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharms Inc | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Agios Pharms Inc | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Agios Pharms Inc | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ivosidenib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 201843136 | Start Trial |
| European Patent Office | 3447052 | Start Trial |
| Taiwan | I636040 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
